X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23) 23
index medicus (23) 23
male (21) 21
middle aged (20) 20
female (19) 19
abridged index medicus (18) 18
cardiac & cardiovascular systems (16) 16
aged (15) 15
secondary prevention (13) 13
treatment outcome (13) 13
myocardial infarction (12) 12
myocardial infarction - drug therapy (12) 12
double-blind method (11) 11
heart attacks (11) 11
heart attack (9) 9
prevention (9) 9
stroke (9) 9
care and treatment (8) 8
medicine, general & internal (8) 8
patients (8) 8
risk factors (8) 8
acute coronary syndromes (7) 7
analysis (7) 7
cardiovascular diseases (7) 7
clopidogrel (7) 7
dosage and administration (7) 7
hemorrhage - chemically induced (7) 7
kaplan-meier estimate (7) 7
risk (7) 7
stroke - prevention & control (7) 7
ticagrelor (7) 7
atherosclerosis (6) 6
cardiovascular disease (6) 6
cardiovascular diseases - mortality (6) 6
myocardial infarction - diagnosis (6) 6
myocardial infarction - mortality (6) 6
peripheral vascular disease (6) 6
pyridines - therapeutic use (6) 6
safety (6) 6
acute coronary syndrome (5) 5
adenosine - analogs & derivatives (5) 5
aspirin (5) 5
cardiology (5) 5
cardiovascular diseases - prevention & control (5) 5
cerebral infarction (5) 5
drug administration schedule (5) 5
drug therapy (5) 5
follow-up studies (5) 5
lactones - therapeutic use (5) 5
mortality (5) 5
myocardial infarction - prevention & control (5) 5
platelet aggregation inhibitors - therapeutic use (5) 5
transluminal angioplasty (5) 5
adenosine - administration & dosage (4) 4
antiplatelet therapy (4) 4
bleeding (4) 4
cardiac patients (4) 4
coronary heart disease (4) 4
coronary vessels (4) 4
diabetes mellitus (4) 4
electrocardiography (4) 4
ischemia (4) 4
myocardial infarction - therapy (4) 4
platelet aggregation inhibitors - adverse effects (4) 4
pyridines - adverse effects (4) 4
secondary prevention - methods (4) 4
thrombolytic therapy (4) 4
time factors (4) 4
trial (4) 4
usage (4) 4
acute coronary syndrome - drug therapy (3) 3
adenosine - adverse effects (3) 3
adult (3) 3
angioplasty (3) 3
arteriosclerosis (3) 3
cardiovascular outcomes (3) 3
cholesterol (3) 3
clinical outcomes (3) 3
clinical trials (3) 3
coronary angiography (3) 3
death (3) 3
diabetes (3) 3
disease prevention (3) 3
health aspects (3) 3
health risk assessment (3) 3
heart-disease (3) 3
human health and pathology (3) 3
lactones - adverse effects (3) 3
life sciences (3) 3
myocardial infarction - epidemiology (3) 3
myocardial infarction - metabolism (3) 3
myocardial ischemia - prevention & control (3) 3
peripheral arterial disease (3) 3
peripheral arterial disease - drug therapy (3) 3
prediction (3) 3
purinergic p2y receptor antagonists - administration & dosage (3) 3
randomization (3) 3
receptor, par-1 - antagonists & inhibitors (3) 3
recurrence (3) 3
vorapaxar (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Liver | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 08/2019, Volume 12, Issue 16, pp. 1553 - 1561
The study sought to evaluate the effect of dabigatran dual therapy versus warfarin triple therapy across categories of renal function in the RE-DUAL PCI... 
warfarin triple therapy | renal function | atrial fibrillation | dabigatran dual therapy | percutaneous coronary intervention | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | SAFETY | PREVENTION | TIME | ANTICOAGULATION | STROKE | TRIAL | WARFARIN | RANGE
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article